our technology
Proprietary ExoSort Platform
More than 91% of RNA/protein Require NDEs for Blood Detection
Alpha Synuclein (non-brain-specific)
80% of all genes are expressed in the brain, only 0.6% are highly specific to the brain, and an additional 9% are enriched in the brain. 90% of the genes that are expressed in the brain are not specific and can not serve as biomarkers.
NFL (brain-specific protein)
The ExoSort Platform offers increased specificity toward the brain, enabling the detection of differences in proteins that are disease-specific but not brain-specific, such as alpha-synuclein. While the ExoSort Platform does not provide a significant benefit for the analysis of NFL, it does enable the detection of alpha-synuclein pathology.
NeuroDex Biomarker Panel: TDP43
Assay qualification completed (below 20% assay variability). Successful collaboration with over 7 pharma.
TDP43 is a key blood biomarker for ALS and FTD. Critical for clinical trials’ success.
Over 100 ongoing ALS clinical trials
NeuroDex Biomarker
for Parkinson’s Disease and Lewy Body
Blood Neuron-derived EVs Alpha-synuclein concordance with CSF seeding assay
- Assay qualification completed (CV<15%)
- High accuracy of predicting CSF a-Syn seeding positivity
- Over 80% sensitivity and specificity with N=150 clinically diagnosed PD and LBD
Ongoing 1100 sample study from PPMI (Parkinson’s Progression Markers Initiative) supported by MJFF
RNAseq of 1100 sample study completed (250 PD and 150 healthy, three time points each) in collaboration with TGEN (NIH funded). More than 90% QC success, high batch-to-batch reproducibility (R=0.93)
